Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Calculators
Our Services
My Account
Do not call
En
Learn about Sahajanand Medical Technologies’ Draft Red Herring Prospectus (DRHP) filing, business operations, financial context, and the proposed utilisation of funds as outlined in public disclosures.
Sahajanand Medical Technologies has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) as part of its plan to raise capital through an initial public offering. The DRHP outlines the company’s business profile, operational capabilities, financial overview, and the broad structure of the proposed public issue.
The DRHP provides an overview of the proposed IPO and sets out the company’s financials, governance framework, and business outlook.
Sahajanand Medical Technologies filed its Draft Red Herring Prospectus with SEBI in July 2025, formally initiating the IPO regulatory process. The filing is currently under regulatory review, following which SEBI observations and approvals will determine the next stages, including the filing of the Red Herring Prospectus (RHP) and announcement of issue dates.
The equity shares are proposed to be listed on recognised stock exchanges in India, subject to regulatory approvals.
As per the DRHP, the proposed IPO is expected to comprise the following components:
| Particulars | Details |
|---|---|
Issue Type |
Fresh Issue of Equity Shares + Offer for Sale (OFS) |
Fresh Issue |
Proceeds to be received by the company |
Offer for Sale |
Partial exit by existing shareholders |
Face Value |
To be disclosed in RHP |
Issue Size |
To be finalised post price discovery |
Proposed Listing |
NSE and BSE |
Price Band |
To be announced in RHP |
Issue Method |
Book Building Issue |
These details reflect indicative disclosures available at the DRHP stage and are subject to change based on SEBI observations and final approvals.
Sahajanand Medical Technologies operates in the medical devices and interventional cardiology segment, specialising in the design, manufacturing, and distribution of cardiovascular medical devices. The company’s product portfolio includes stents, balloons, catheters, and other interventional cardiology devices, catering to hospitals and healthcare providers across India and international markets.
The company operates manufacturing facilities equipped with advanced medical device production technology, quality assurance systems, and regulatory compliance infrastructure. Its business model is centred on research-driven product development, clinical validation, regulatory approvals, and long-term relationships with healthcare institutions and distributors.
Sahajanand Medical Technologies benefits from India’s expanding medical devices ecosystem, driven by rising cardiovascular disease prevalence, increasing healthcare spending, and growing adoption of advanced cardiac intervention procedures.
According to the DRHP, the proceeds from the fresh issue are proposed to be utilised towards the following broad objectives:
| Fund Allocation | Purpose |
|---|---|
Capital Expenditure |
Expansion of manufacturing facilities, advanced production equipment, sterile manufacturing infrastructure, and quality testing laboratories |
Research & Development |
Development of new interventional cardiology and medical devices, product innovation, clinical trials, and regulatory submissions |
Working Capital |
Inventory procurement, distributor channel support, and operational requirements |
Debt Repayment |
Partial repayment of borrowings to optimise capital structure |
General Corporate Purposes |
Administrative expenses and strategic flexibility |
These objectives are aimed at strengthening manufacturing capacity, advancing medical device technology, and supporting long-term growth in the healthcare and medical devices sector.
The DRHP provides an overview of Sahajanand Medical Technologies’ financial performance, offering insight into its operational scale and profitability trends.
| Fiscal Year / Period | Revenue | EBITDA | Profit After Tax (PAT) |
|---|---|---|---|
FY24 |
As per DRHP |
As per DRHP |
As per DRHP |
FY25 |
As per DRHP |
As per DRHP |
As per DRHP |
H1 FY26 |
As per DRHP |
As per DRHP |
As per DRHP |
*Detailed year-wise financial statements, including audited figures, are available in the DRHP and should be referred to for complete financial information.
The table below summarises the current status of the IPO process based on publicly available information:
| Milestone / Stage | Date (or Status) | Details |
|---|---|---|
DRHP filed with SEBI |
July 2025 |
Draft Red Herring Prospectus filed for regulatory review |
SEBI observations /approval |
November 2025 |
SEBI observations received, enabling progression to next stage |
Red Herring Prospectus (RHP) |
To be filed |
To be filed after incorporating SEBI observations |
IPO Opening Date |
To be announced |
Final dates awaited |
IPO Closing Date |
To be announced |
To be disclosed in RHP |
Allotment Date |
To be announced |
Post IPO closure |
Listing on NSE/BSE |
To be announced |
Subject to allotment and approvals |
Note: Investors should refer to official filings for final IPO dates to learn more about Sahajanand Medical Technologies IPO listing details and price, and listing timelines.
This content is for informational purposes only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Sources
LiveMint — IPO News and Updates, https://www.livemint.com/market/ipo
Economic Times — IPO News: Latest IPO News, Upcoming IPO, https://economictimes.indiatimes.com/markets/ipo
Financial Express — IPO News, https://www.financialexpress.com/market/ipo-news/
NDTV Profit — IPOs, https://www.ndtvprofit.com/ipos
Business Today — IPO Corner: Latest IPO News & Analysis, https://www.businesstoday.in/markets/ipo-corner
Sahajanand Medical Technologies filed its Draft Red Herring Prospectus with the Securities and Exchange Board of India in July 2025, formally initiating the regulatory process for its initial public offering in the Indian capital markets.
The Sahajanand Medical Technologies IPO has received observations from the Securities and Exchange Board of India (SEBI), clearing the company to proceed with the filing of the Red Herring Prospectus (RHP). The IPO is now in the pre-launch stage, with issue details such as price band and opening dates yet to be announced.
The Sahajanand Medical Technologies IPO comprises a fresh issue of equity shares along with an offer for sale by existing shareholders, with the final issue size and pricing to be determined through the book-building process.
Subject to regulatory approvals, Sahajanand Medical Technologies equity shares are proposed for listing on both the National Stock Exchange and the Bombay Stock Exchange, facilitating investor access and market liquidity post-issue.
Sahajanand Medical Technologies intends to utilise fresh issue proceeds for manufacturing expansion, research and development initiatives, working capital requirements, partial debt repayment, and general corporate purposes to drive growth in the medical devices sector.
.jpeg)
250 Views
| 1min read
Posted on 19 Dec
Academy 
.jpeg "image not found"){kind=small}
